Highlights  

Predictive Oncology launched a new digital asset treasury strategy centered on the ATH token. 

  • The company secured approximately USD 50.8M in cash proceeds and USD 292.7M in in-kind ATH contributions. 
  • Predictive Oncology now holds around 5.70 billion ATH tokens as of November 10, 2025. 
  • The company expanded its leadership with the appointment of Shawn Matthews to its Board of Directors. 
  • Q3 revenue remained steady, while operating expenses reflected higher legal and stock-based compensation costs. 

Predictive Oncology (POAI:NASDAQ) entered Q3 2025 with a focus on transforming its business model by integrating a digitalassetstrategy into its traditionalAI-driven drug discovery platform. The centerpiece of this expansion is the company’s treasury strategy centered on ATH, the native utility token of the Aethir ecosystem. Two private placements provided a combined USD 50.8M in cash proceeds and in-kind locked and unlocked ATH valued at USD 292.7M at signing. 

As of November 10, 2025, the company held approximately 5.70 billion ATH, of which 3.7 billion remain locked under vesting or transfer restrictions. The remaining 2.0 billion ATH is unlocked. Based on the Coinbase-listed price of USD 0.0268 per token, the company's holdings carried amarket valueof USD 152.8M. 

This strategic shift positions Predictive Oncology as an operator within Aethir’s decentralized compute network, giving it the ability to potentially generate utility and revenue from its Strategic Compute Reserve. The company sees this initiative as an opportunity to help address global demand for high-performance AI infrastructure while unlocking value across sectors that face compute shortages. 

Business Enhancements and Strategic Collaborations 

In addition to its digital asset strategy, Predictive Oncology strengthened its leadership by appointing Shawn Matthews, CEO of DNA Holdings and former CEO of Cantor Fitzgerald, to its Board of Directors. The move supports the company’s ambition to expand its operational and financial capabilities. 

Predictive Oncology also advanced its collaboration activities, including a new partnership with Every Cure to accelerate drug repurposing across multiple disease areas. This initiativeleveragesthe company’s PEDAL AI platform, which predicts with 92% accuracy whether a tumor sample will respond to a given drug. Combined with a biobank containing more than 150,000 human tumor samples, Predictive Oncology continues to build one of the most comprehensive AI-driven drug discovery ecosystems in the sector. 

Q3 2025 Financial Performance 

The company recorded revenue of USD 3,618 for Q3 2025, largely consistent with the USD 3,907 posted in the same quarter of 2024. General and administrative expenses increased to USD 2.6M, primarily due to elevated legal costs and stock-based compensation. Research and development expenses remained stable at approximately USD 528,557. 

Predictive Oncology posted a basic and diluted loss per share of USD (107.24), compared to USD (4.99) in Q3 2024. The steep year-over-year change reflects a USD 74.4Mderivativeliabilitytied to the launch of the ATH-focused digital asset strategy. The company ended the quarter with USD 181,667 in cash and cash equivalents from continuing operations and a stockholders’ deficit of USD 77.4M. 

Conclusion 

Predictive Oncology’s third-quarter performance reflects a period of significant transition as the company broadens its business beyond drug discovery into digital asset-enabled AI infrastructure. With its Strategic Compute Reserve aimed at supporting global enterprise compute demand and its continued commitment to AI-based oncology innovations, the company is positioning itself for a future that integrates technology, compute, and precision medicine. While financial challenges remain, Predictive Oncology’s new strategy aims to create long-term pathways for revenue generation and operational expansion.